Cargando…

Immune-Based Therapies for Sarcoma

Immunotherapy has shown promise in a number of tumor types, but its exact role in sarcoma remains to be defined. Advanced bone and soft tissue sarcomas are challenging diseases to treat with an unmet need for effective systemic therapy. Previous reports have suggested that immune-based treatments ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollack, Seth M., Loggers, Elizabeth T., Rodler, Eve T., Yee, Cassian, Jones, Robin L.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034923/ https://www.ncbi.nlm.nih.gov/pubmed/21331153 http://dx.doi.org/10.1155/2011/438940

Ejemplares similares

Systemic therapy in primary angiosarcoma of the spleen
por: Ferreira, Bruna Pellini, et al.
Publicado: (2012)

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine
por: Pollack, Seth M., et al.
Publicado: (2012)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Propranolol for the treatment of vascular sarcomas
por: Wagner, Michael J, et al.
Publicado: (2018)

Optimising Cancer Vaccine Design in Sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
por: Riedel, Richard F., et al.
Publicado: (2018)

Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years
por: Rainey, David, et al.
Publicado: (2015)

Multiple Liver Abscess Formation and Primary Gastrointestinal Stromal Tumor
por: E. Chang, Amy, et al.
Publicado: (2013)

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
por: Yee, Cassian
Publicado: (2005)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Drug repositioning in sarcomas and other rare tumors
por: Lee, Alex T.J., et al.
Publicado: (2016)

Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy
por: Schroeder, Brett A, et al.
Publicado: (2020)

Targeting cancer testis antigens in synovial sarcoma
por: Mitchell, Geoffrey, et al.
Publicado: (2021)

The Effect of Radiation on the Immune Response to Cancers
por: Park, Bonggoo, et al.
Publicado: (2014)

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
por: Pollack, Seth M., et al.
Publicado: (2020)

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021)

Response to PD1 inhibition in conventional chondrosarcoma
por: Wagner, Michael J., et al.
Publicado: (2018)

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)
por: Kasper, Bernd, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
por: Mc Laughlin, Anna M., et al.
Publicado: (2023)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients
por: Pollack, Seth M.
Publicado: (2017)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment
por: Shibuya, Kendall C., et al.
Publicado: (2014)

Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy
por: Mc Laughlin, Anna M, et al.
Publicado: (2023)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas
por: Pollack, Seth M., et al.
Publicado: (2017)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Targeted therapy for sarcomas
por: Forscher, Charles, et al.
Publicado: (2014)

2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma
por: Frezza, Anna Maria, et al.
Publicado: (2018)

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
por: Roszik, Jason, et al.
Publicado: (2017)

Targeted Therapy in Ewing Sarcoma
por: Lissat, A., et al.
Publicado: (2012)

Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy
por: Noujaim, Jonathan, et al.
Publicado: (2015)

Epidemiology and therapies for metastatic sarcoma
por: Amankwah, Ernest K, et al.
Publicado: (2013)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eccfsc94opvjmlbclumidnfj84